# US 2010/0145061 A1 · N-(1-phenyl-2-arylethyl)-4,5-dihydro-2h-pyrrol-5-amine compounds as subtype selective modulators of alpha2b or alpha2b and alpha2c adrenoceptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0145061 A1
- Document ID: US20100145061A1
- Status: Published application
- Kind: A1
- Application number: 12/632,494
- Filed: 2009-12-07
- Published: 2010-06-10
- Earliest claimed: 2008-12-08
- Assignees: Allergan, Inc.
- Inventors: Ken Chow; Janet A. Takeuchi; Ling Li; Todd M. Heidelbaugh; Phong X. Nguyen; Evelyn G. Corpuz; Wenkui K. Fang; Santosh C. Sinha; Michael E. Garst
- Web page: https://patentgrep.com/patent/US20100145061A1

## CPC

- C07D 207/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds which are N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds and are subtype selective modulators of alpha 2B or alpha 2B and alpha 2C adrenoreceptors and are selected from the group of compounds represented by the formula

## Claims

### Claim 1

Novel compounds which are N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds and are subtype selective modulators of alpha2B or alpha2B and alpha2C adrenoceptors and are useful in treating diseases that include but are not limited to chronic pain, visceral pain, corneal pain, neuropathic pain, glaucoma, ischemic neuropathies and other neurodegenerative diseases selected from the group of compounds represented by the formula
wherein R is selected from the group consisting of H, lower alkyl, alkenyl, alkynyl, cycloalkyl, aryl, lower alkyloxy, hydroxyl, halogen, nitrile, trifluoromethyl, amino, thio, nitro and carboxy groups;
Ar is an aryl group, wherein said aryl group may be bonded to the above moiety at any position and wherein said aryl group may be unsubstituted or may be substituted with any common organic functional group and
n is an integer of from 1 to 5.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein Ar is a carbocyclic or heterocyclic aryl group selected from the group consisting of benzene, pyridine, thiophene, furan, naphthalene, quinoline, indan, and benzofuran groups.

### Claim 3 (depends on 1)

A compound according to claim 1 wherein Ar is unsubstituted or is substituted with one or more alkyl, alkenyl, alkynyl, alkoxy, aryl, halogen, hydroxyl, amino, nitrile, nitro, thio, or carboxy groups.

### Claim 4 (depends on 1)

A compound according to claim 1 wherein R is selected from the group consisting of H, lower alkyl, lower alkyloxy, fluoro, chloro and bromo groups.

### Claim 5 (depends on 2)

A compound according to claim 2 wherein Ar is a selected from the group consisting of benzene and pyridine groups.

### Claim 6 (depends on 5)

A compound according to claim 5 wherein R is selected from the group consisting of H, fluoro, chloro, and methyl.

### Claim 7 (depends on 5)

A compound according to claim 5 wherein Ar is selected from the group consisting of phenyl, which may be unsubstituted or substituted with one or two halogen groups selected from the group consisting of fluoro, chloro and bromo, and/or one methyl group or one methoxy group and pyridyl, which may be unsubstituted or substituted with one or two methyl groups, and one bromo group or one chloro group.

### Claim 8 (depends on 7)

A compound according to claim 7 having selectivity for the 2B adrenergic receptor subtype and absent any 2C adrenergic receptor subtype activity, wherein R is H or mono or dichloro or dimethyl or fluoro, chloro and Ar is selected from the group consisting of phenyl, which may be unsubstituted or substituted with one or two halogen groups selected from the group consisting of fluoro, chloro and bromo and/or one methyl, and/or one methoxy, and pyridyl, which may be unsubstituted or substituted with one or two methyl groups and one bromo or one chloro group.

### Claim 9 (depends on 5)

A compound according to claim 5 having activity at the 2B adrenergic receptor subtype, wherein the EC50 activity is less than 5 nM, wherein R is dimethyl or mono or dichloro and Ar is selected from the group consisting of phenyl, which may be unsubstituted or substituted with two chloro groups or one methyl group, and pyridyl which may be unsubstituted or substituted with one methyl or one chloro group.

### Claim 10 (depends on 1)

A compound according to claim 1 selected from the group consisting of

### Claim 11 (depends on 1)

The use of a compound according to claim 1 to treat chronic pain, visceral pain, corneal pain, neuropathic pain, glaucoma, ischemic neuropathies and other neurodegenerative diseases.

### Claim 12 (depends on 1)

The use of a compound according to claim 1 to manufacture a medicament to treat chronic pain, visceral pain, corneal pain, neuropathic pain, glaucoma, ischemic neuropathies and other neurodegenerative diseases.
